- Home
- COUR vs BCYC Comparison
COUR vs BCYC Comparison
Compare COUR & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COUR
- BCYC
- Stock Information
- Founded
- COUR 2012
- BCYC 2009
- Country
- COUR United States
- BCYC United Kingdom
- Employees
- COUR N/A
- BCYC N/A
- Industry
- COUR Computer Software: Prepackaged Software
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- COUR Technology
- BCYC Health Care
- Exchange
- COUR Nasdaq
- BCYC Nasdaq
- Market Cap
- COUR 1.5B
- BCYC 566.5M
- IPO Year
- COUR 2021
- BCYC 2019
- Fundamental
- Price
- COUR $8.49
- BCYC $7.71
- Analyst Decision
- COUR Hold
- BCYC Buy
- Analyst Count
- COUR 13
- BCYC 10
- Target Price
- COUR $10.37
- BCYC $25.00
- AVG Volume (30 Days)
- COUR 1.5M
- BCYC 303.4K
- Earning Date
- COUR 07-24-2025
- BCYC 08-05-2025
- Dividend Yield
- COUR N/A
- BCYC N/A
- EPS Growth
- COUR N/A
- BCYC N/A
- EPS
- COUR N/A
- BCYC N/A
- Revenue
- COUR $704,874,000.00
- BCYC $25,722,000.00
- Revenue This Year
- COUR $6.70
- BCYC $7.35
- Revenue Next Year
- COUR $4.88
- BCYC N/A
- P/E Ratio
- COUR N/A
- BCYC N/A
- Revenue Growth
- COUR 7.25
- BCYC N/A
- 52 Week Low
- COUR $5.76
- BCYC $6.10
- 52 Week High
- COUR $11.74
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- COUR 49.43
- BCYC 55.77
- Support Level
- COUR $7.98
- BCYC $7.06
- Resistance Level
- COUR $8.94
- BCYC $8.17
- Average True Range (ATR)
- COUR 0.28
- BCYC 0.38
- MACD
- COUR -0.03
- BCYC 0.12
- Stochastic Oscillator
- COUR 54.17
- BCYC 92.69
About COUR Coursera Inc.
Coursera Inc is an online learning platform that connects learners, educators, and institutions with the goal of providing educational content that is affordable, accessible, and relevant. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The company operates through three reporting segments: Consumer, Enterprise, and Degrees. The majority of revenue is generated from the Consumer segment. The consumer segment targets individual learners seeking to obtain hands-on learning, gain valuable job skills, receive professional-level certifications, and otherwise increase their knowledge to start or advance their careers.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.